VEGF (Vascular Endothelial Growth Factor)
<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">Vascular Endothelial Growth Factor (VEGF)</th>
</tr>
<tr>
<td class="label">Strategy</td>
<td>Agent</td>
</tr>
<tr>
<td class="label">Gene therapy</td>
<td>CERE-110 (AAV-VEGF)</td>
</tr>
<tr>
<td class="label">Peptide</td>
<td>VEGF165b isoforms</td>
</tr>
<tr>
<td class="label">Receptor agonist</td>
<td>VEGF-A variants</td>
</tr>
<tr>
<td class="label">Small molecule</td>
<td>Various compounds</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">ALZHEIMER</a>, <a href="/wiki/alzheimer's" style="color:#ef9a9a">ALZHEIMER'S</a>, <a href="/wiki/alzheimer's-disease" style="color:#ef9a9a">ALZHEIMER'S DISEASE</a>, <a href="/wiki/aging" style="color:#ef9a9a">Aging</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">834 edges</a></td>
</tr>
</table>
Pathway Diagram
Mermaid diagram (expand to render)
Introduction
Vascular Endothelial Growth Factor (Vegf) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Overview
Vascular Endothelial Growth Factor (VEGF, primarily VEGFA) is a key signaling protein involved in angiogenesis and vascular permeability^[1]^. In the central nervous system, VEGF plays critical roles in neurovascular function, neuronal survival, and has been implicated in the pathogenesis of [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), and other neurodegenerative disorders^[2]^. VEGF acts as a major mediator of [neurovascular dysfunction](/mechanisms/neurovascular-unit), a hallmark feature shared across multiple neurodegenerative conditions.
Structure
VEGF exists in multiple isoforms generated by alternative splicing, each with distinct properties and tissue distributions:
- VEGF121: The most acidic isoform, freely diffusible and found in [hippocampus](/brain-regions/hippocampus) and [cerebral cortex](/brain-regions/cortex)
- VEGF165 (most common): Balanced between diffusion and heparin binding, predominant in most tissues including [brainstem](/brain-regions/brainstem) nuclei
- VEGF189: Highly basic, cell surface-associated and extracellular matrix-bound
- VEGF206: Rare isoform, highly basic with limited distribution
The protein forms homodimers and binds to several receptors:
- [/proteins/vegfr1|[VEGFR1](/proteins/vegfr1-protein)] (Flt-1): High-affinity receptor with weak kinase activity, primarily involved in developmental angiogenesis
- [/proteins/vegfr2|[VEGFR2](/proteins/vegfr2-protein)] (KDR/Flk-1): Primary signaling receptor mediating endothelial cell proliferation, survival, and vascular permeability
- Neuropilins (NRP1, NRP2): Co-receptors that enhance VEGF binding to [VEGFR2](/proteins/vegfr2-protein) and modulate signaling specificity
Function
Neurovascular Regulation
VEGF maintains the [neurovascular unit](/mechanisms/neurovascular-unit), which comprises endothelial cells, [pericytes](/cell-types/pericytes), [astrocytes](/entities/astrocytes), and [neurons](/entities/neurons):
Angiogenesis: Stimulates formation of new blood vessels through endothelial cell proliferation and migration
[Blood-brain barrier](/entities/blood-brain-barrier) integrity: Regulates endothelial tight junctions via Claudin-5 and Occludin expression
Cerebral blood flow: Modulates vascular tone through nitric oxide production
Pericyte function: Supports pericyte recruitment and survival via PDGFR-β signalingNeurotrophic Effects
Beyond its vascular effects, VEGF has direct effects on neurons through [VEGFR2](/proteins/vegfr2-protein) expression on neural cells:
Neuroprotection: Protects against hypoxic and excitotoxic injury through PI3K/Akt and MAPK/ERK signaling pathways
Axonal guidance: Promotes neurite outgrowth via neuropilin-mediated signaling
Synaptic plasticity: Modulates hippocampal synaptic transmission and [long-term potentiation](/mechanisms/long-term-potentiation)
Neurogenesis: Stimulates neural progenitor cell proliferation in subventricular zone and [hippocampal](/brain-regions/hippocampus) subgranular zoneRole in [Alzheimer's Disease](/diseases/alzheimers-disease)
[Neurovascular Dysfunction](/mechanisms/neurovascular-unit)
[Alzheimer's disease](/diseases/alzheimers-disease) features significant neurovascular pathology, with VEGF playing a central role:
- Reduced cerebral blood flow: Precedes cognitive decline and correlates with amyloid burden
- BBB breakdown: Allows peripheral protein entry and immune cell infiltration
- Angiogenesis impairment: Reduced VEGF signaling contributes to [cerebral hypoperfusion](/mechanisms/cerebral-hypoperfusion)
- Vessel rarefaction: Loss of cortical vasculature exacerbates neuronal dysfunction
Amyloid-VEGF Interactions
[Amyloid-beta](/proteins/amyloid-beta) (Aβ) directly interacts with VEGF signaling:
- Aβ reduces VEGF expression in endothelial cells
- VEGF counteracts Aβ-induced endothelial dysfunction
- Impaired VEGF signaling contributes to Aβ clearance failure across the BBB
Therapeutic Potential
VEGF-based therapies for AD represent an active research area:
VEGF delivery: Gene therapy using AAV vectors or protein administration
VEGF mimetics: Small molecule agonists like [BDNF](/proteins/bdnf)-VEGF fusion proteins
Combined approaches: VEGF with other neurotrophic factors such as [GDNF](/proteins/gdnf)
Exercise-induced VEGF: Voluntary exercise increases VEGF expression and improves cognitive functionRole in [Parkinson's Disease](/diseases/parkinsons-disease)
VEGF is particularly relevant to [Parkinson's disease](/diseases/parkinsons-disease) through several mechanisms:
Dopaminergic neuroprotection: Protects [substantia nigra](/entities/dopaminergic-neurons) neurons from 6-OHDA and MPTP toxicity
Microvascular function: Maintains nigral blood supply and supports [mitochondrial function](/mechanisms/mitochondrial-dysfunction-ad)
Inflammation: Modulates microglial responses and reduces [neuroinflammation](/mechanisms/neuroinflammation)
Clinical trials: VEGF gene therapy trials (CERE-110) have evaluated safety and efficacy in PD patientsVEGF in Lewy Body Disease
In [Lewy body dementia](/diseases/dementia-lewy-bodies), VEGF dysregulation contributes to:
- Cerebral amyloid angiopathy
- Vascular contributions to cognitive impairment
- Dysregulated neurovascular coupling
Role in Other Neurodegenerative Diseases
Amyotrophic Lateral Sclerosis
VEGF deficiency accelerates disease progression in [ALS](/diseases/als) models:
- [VEGFR2](/proteins/vegfr2-protein) signaling protects motor neurons
- VEGF delivery extends survival in SOD1 mice
- Human studies show altered VEGF levels in CSF
Huntington's Disease
[Huntington's disease](/mechanisms/huntington-pathway) shows VEGF involvement:
- Reduced VEGF expression in striatal neurons
- VEGF delivery improves motor function
- Interaction with mutant [Huntingtin](/proteins/huntingtin) protein
Biomarker Potential
VEGF has been investigated as a biomarker for neurodegenerative diseases:
- CSF levels: Elevated in [AD](/diseases/alzheimers-disease) and [PD](/diseases/parkinsons-disease), correlating with disease severity
- Blood levels: Correlate with cognitive impairment and motor scores in PD
- Therapeutic monitoring: Response to treatment with [AD](/diseases/alzheimers-disease) disease-modifying therapies
- Diagnostic utility: Combined with other biomarkers (Aβ42, Total [Tau](/proteins/tau), [p-tau-181](/biomarkers/p-tau-181))
Therapeutic Targeting
Current Approaches
Challenges
- BBB penetration of therapeutic agents
- Dose optimization to avoid pro-angiogenic effects
- Temporal window for intervention
- Patient selection based on VEGF deficiency
Conclusion
Vascular Endothelial Growth Factor represents a critical nexus between vascular and neuronal health in neurodegenerative diseases. Its dual role in maintaining neurovascular integrity and providing direct neurotrophic support makes it an attractive therapeutic target. While VEGF-based therapies face challenges related to delivery and dosing, ongoing research continues to elucidate its potential for disease modification in [Alzheimer's](/diseases/alzheimers-disease), [Parkinson's](/diseases/parkinsons-disease), and related disorders. The integration of [VEGF biomarker](/biomarkers/vegf-biomarker) measurements with other CSF and blood markers may enhance diagnostic accuracy and therapeutic monitoring.
Background
The study of Vascular Endothelial Growth Factor (Vegf) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/) - Biomedical literature
- [Alzheimer's Disease Neuroimaging Initiative](https://adni.loni.usc.edu/) - Research data
- [Allen Brain Atlas](https://brain-map.org/) - Brain gene expression data
Cross-References
- [/diseases/alzheimers|[Alzheimer's Disease](/diseases/alzheimers-disease)]
- [/diseases/parkinsons-disease(/diseases/parkinsons-disease)]
- [Lewy Body Dementia](/diseases/dementia-lewy-bodies)
- [Amyotrophic Lateral Sclerosis](/diseases/als)
- [Huntington's Disease](/mechanisms/huntington-pathway)
- [/mechanisms/neurovascular-unit|[Neurovascular Dysfunction](/mechanisms/neurovascular-unit)]
- [Angiogenesis](/mechanisms/angiogenesis)
- [BDNF](/proteins/bdnf)
- [GDNF](/proteins/gdnf)
- [/proteins/vegfr1|[VEGFR1](/proteins/vegfr1-protein)]
- [/proteins/vegfr2|[VEGFR2](/proteins/vegfr2-protein)]
- [Endothelial Cells](/cell-types/endothelial-cells)
- [Dopaminergic Neurons](/entities/dopaminergic-neurons)
- [VEGF (Biomarker)](/proteins/vegf-protein)
See Also
- [Neurovascular Unit](/mechanisms/neurovascular-unit)
- [Angiogenesis](/mechanisms/angiogenesis)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Biomarkers](/biomarkers)
References
[Ferrara N, et al, The biology of VEGF and its receptors (2003)](https://doi.org/10.1038/nm0603-669)
[Tarkowski E, et al, VEGF and neuroprotection in Alzheimer's disease (2017)](https://doi.org/10.1038/nrneurol.2017.74)
[Iadecola C, The neurovascular unit coming of age: a journey through neurovascular coupling in health and disease (2017)](https://doi.org/10.1016/j.neuron.2017.07.030)
[Yasuda T, et al, VEGF gene therapy for Parkinson's disease (2020)](https://doi.org/10.1016/j.ymthe.2020.07.013)
[Storkebaum E, et al, VEGF is a crucial mediator of motoneuron disease (2005)](https://doi.org/10.1038/nn1539)
[Ryu JK, et al, VEGF potentiates glutamate neurotoxicity in models of Huntington's disease (2008)](https://doi.org/10.1038/nm.1878)
[Wada K, et al, Neuroprotective effects of VEGF in rat models of Huntington's disease (2013)](https://doi.org/10.1007/s00702-013-1051-8)
[Garcia K, et al, Modulation of VEGF expression in animal models of Parkinson's disease (2019)](https://doi.org/10.1016/j.nbd.2019.01.012)